{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:04:30Z","timestamp":1756425870373,"version":"3.44.0"},"reference-count":13,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,7,25]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>In this report, we describe the case of an adolescent male with an unusual case of fusion-negative, paratesticular alveolar rhabdomyosarcoma who presented with spontaneous tumour lysis syndrome and diffuse bony metastases throughout the axial and appendicular skeleton with additional significant bone marrow involvement. Both spontaneous tumour lysis syndrome and diffuse bony metastases are extremely unusual for rhabdomyosarcoma. On the backbone of standard vincristine, dactinomycin and cyclophosphamide (VAC) chemotherapy, the only local control was orchiectomy at 15 weeks, with no radiation administered due to the initially diffuse nature of the disease and rapid response to chemotherapy. Following 43 weeks of VAC, a year-long maintenance phase with pazopanib was given which was well tolerated. The patient remains in remission now 4\u2009years after completion of therapy.<\/jats:p>","DOI":"10.1136\/bcr-2022-250236","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T11:30:19Z","timestamp":1661772619000},"page":"e250236","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Fusion-negative rhabdomyosarcoma with diffuse bony metastases and remarkable chemosensitivity"],"prefix":"10.1136","volume":"15","author":[{"given":"Paige","family":"Kube","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Nemours Children's Hospital Delaware, Wilmington, Delaware, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Parisio","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology and Department of Palliative Medicine, Nemours Children's Hospital Delaware, Wilmington, Delaware, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Spencer","family":"Mangum","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, University of Utah and Primary Children's Hospital, Salt Lake City, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8306-5162","authenticated-orcid":false,"given":"Jonathan","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nemours Children's Hospital Delaware, Wilmington, Delaware, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"2025082804245107000_15.8.e250236.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.7207"},{"key":"2025082804245107000_15.8.e250236.2","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1002\/cam4.2504","article-title":"Refinement of risk stratification for childhood rhabdomyosarcoma using FoxO1 fusion status in addition to established clinical outcome predictors: a report from the children's Oncology Group","volume":"8","author":"Hibbitts","year":"2019","journal-title":"Cancer Med"},{"key":"2025082804245107000_15.8.e250236.3","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26809","article-title":"Consensus and controversies regarding the treatment of rhabdomyosarcoma","volume":"65","author":"Borinstein","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2025082804245107000_15.8.e250236.4","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/ijc.33143","article-title":"Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: a report from the children's Oncology Group soft tissue sarcoma Committee","volume":"147","author":"Routh","year":"2020","journal-title":"Int J Cancer"},{"key":"2025082804245107000_15.8.e250236.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3814"},{"key":"2025082804245107000_15.8.e250236.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-016-0552-9","article-title":"Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literature","volume":"11","author":"Balogh","year":"2016","journal-title":"Diagn Pathol"},{"key":"2025082804245107000_15.8.e250236.7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/pbc.21783","article-title":"Rhabdomyosarcoma masquerading as acute leukemia","volume":"52","author":"Shinkoda","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"2025082804245107000_15.8.e250236.8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pbc.25879","article-title":"Severe tumor lysis syndrome and acute pulmonary edema requiring extracorporeal membrane oxygenation following initiation of chemotherapy for metastatic alveolar rhabdomyosarcoma","volume":"63","author":"Sanford","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"2025082804245107000_15.8.e250236.9","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","article-title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Bisogno","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025082804245107000_15.8.e250236.10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/TCRM.S84792","article-title":"Pazopanib in the management of advanced soft tissue sarcomas","volume":"12","author":"Cranmer","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"2025082804245107000_15.8.e250236.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.0914"},{"key":"2025082804245107000_15.8.e250236.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0272"},{"key":"2025082804245107000_15.8.e250236.13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt586"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-250236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:25:00Z","timestamp":1756380300000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-250236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":13,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,29]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/bcr-2022-250236"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-250236","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}